334009-79-9Relevant academic research and scientific papers
Nonpeptide αvβ3 antagonists. Part 2: Constrained glycyl amides derived from the RGD tripeptide
Meissner, Robert S.,Perkins, James J.,Duong, Le T.,Hartman, George D.,Hoffman, William F.,Huff, Joel R.,Ihle, Nathan C.,Leu, Chih-Tai,Nagy, Rose M.,Naylor-Olsen, Adel,Rodan, Gideon A.,Rodan, Sevgi B.,Whitman, David B.,Wesolowski, Gregg A.,Duggan, Mark E.
, p. 25 - 29 (2007/10/03)
Mimetics of the RGD tripeptide are described that are potent, selective antagonists of the integrin receptor, αvβ3. The use of the 5,6,7,8-tetrahydro[1,8]naphthyridine group as a potency-enhancing N-terminus is demonstrated. Two 3-substituted-3-amino-propionic acids previously contained in αIIbβ3 antagonists were utilized to enhance binding affinity and functional activity for the targeted receptor. Further affinity increases were then achieved through the use of cyclic glycyl amide bond constraints.
Integrin receptor antagonists
-
, (2008/06/13)
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 an
